Additional novel agents with preclinical activity such as ONC212, with the ability to inhibit autophagy, may be well-suited for further study in combination with MEK inhibitors or other agents in pancreatic cancer. The gene discussed is MAP2K7; the disease is pancreatic neoplasm.